Results 91 to 100 of about 43,902 (289)

Nipocalimab Dose Selection in Generalized Myasthenia Gravis

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Model‐Informed Nipocalimab Dose Selection for Generalized Myasthenia Gravis. ABSTRACT Nipocalimab is a fully human immunoglobulin G (IgG)1 monoclonal antibody (mAb) designed to selectively block the IgG binding site of neonatal fragment crystallizable receptor (FcRn) to inhibit IgG recycling and decrease circulating IgG, including pathogenic IgG ...
Belén Valenzuela, Martine Neyens, Yaowei Zhu, Sindhu Ramchandren, Anne‐Gaëlle Dosne, Jocelyn H. Leu, Ruben Faelens, Leona E. Ling, Juan‐José Pérez‐Ruixo   +8 more
wiley   +1 more source

Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review [PDF]

Archives of Endocrinology and Metabolism
SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases.
Lisa Schmitt, Verena Theiler-Schwetz, Patrick Sadoghi, Christian Trummer, Stefan Pilz   +4 more
doaj   +1 more source

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain [PDF]

, 2015
The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in ...
Darbà, Josep, Kaskens, Lisette, Lothgren, Mickael, Sorio Vilela, Francesc   +3 more
core   +1 more source

Immunomodulatory Biomaterials for Bone and Soft Tissue Chronic Inflammation Diseases

Small Science, EarlyView.
This review analyzes immunomodulatory biomaterial strategies for treating chronic inflammatory disorders in bone and soft tissues. It explores emerging mechanisms for resolving inflammation while promoting tissue regeneration, offering insights for developing targeted immunotherapeutic approaches that bridge material science with immunology for ...
Yiming Li, Xudong Xie, Chong Ding, Shengming Zhang, Liangcong Hu, Bobin Mi, Mengfei Liu, Guohui Liu   +7 more
wiley   +1 more source

Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. [PDF]

, 2020
The surgeon general of the USA defines osteoporosis as "a skeletal disorder characterized by compromised bone strength, predisposing to an increased risk of fracture." Measuring bone strength, Biomechanical Computed Tomography analysis (BCT), namely ...
Bouxsein, ML, Clarke, BL, Cosman, F, Keaveny, TM, Khosla, S, Orwoll, ES, Siris, ES   +6 more
core  

Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. [PDF]

, 2014
Women with osteoporosis treated for 36 months with twice-yearly injections of denosumab sustained fewer hip fractures compared with placebo. Treatment might improve femoral bone at locations where fractures typically occur.
Brown, Jacques P, Gee, Andrew H, Libanati, Cesar, McClung, Michael R, Poole, Kenneth ES, Treece, Graham M, Wang, Andrea   +6 more
core   +2 more sources

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature

Endocrinology and Metabolism, 2022
Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption.
W. Tay, D. Tay
semanticscholar   +1 more source

Deciphering epigenetic regulation in postmenopausal osteoporosis: Current and future perspectives

VIEW, EarlyView.
In this perspective, the significant roles of microRNAs, long noncoding RNAs and circular RNAs in postmenopausal osteoporosis are thoroughly expounded. The advantages and limitations of typical noncoding RNAs as diagnostic biomarkers and therapeutic targets are summarized and discussed.
Xiumei Tang, Meiru Chen, Guixuan Xu, Yuan Li, Sen Guo, Yufeng Huang, Zhaoliang Hou, Xiaoling Hou, Zhijian Wei, Wenzhao Wang, Bing Ning   +10 more
wiley   +1 more source

Case report: Denosumab-associated acute heart failure in patients with cardiorenal insufficiency

Frontiers in Endocrinology, 2022
Denosumab is a pivotal treatment for postmenopausal women with osteoporosis. Although its clinical use is generally well tolerated by patients, denosumab in patients with renal insufficiency may increase the risk of hypocalcemia.
Yuexian Xing, Sicong Ju, Mengyu Sun, Shoukui Xiang   +3 more
doaj   +1 more source

Adaptive immunity in cancer immunology and therapeutics. [PDF]

, 2014
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core   +2 more sources